SynthesisWorld journal of surgical oncology2025
Appraising clinicopathological and prognostic significance of circular RNA ubiquitin-associated protein 2 in human cancer.
Synthesis in World journal of surgical oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCircular RNA ubiquitin-associated protein 2 (circUBAP2) is highly expressed in various human cancers and has been identified as a key contributor to cancer development and progression. We performed this study to explore the clinicopathological and prognostic significance of circUBAP2 in multiple cancers.
methodsThis meta-analysis was conducted according to PRISMA 2020 guidelines. PubMed, Web of Science, CNKI, Wanfang, ClinicalTrials.gov and BioXiv were systematically searched from inception to March 1, 2025 according to the PICO framework. Study quality was appraised using the Newcastle-Ottawa Scale and eventually a total of 12 studies with 905 participants were included. Pooled odds ratios (ORs) and hazard ratios (HRs) with 95% confidence intervals (CIs) were synthesized using fixed- or random-effects models based on heterogeneity (I² statistic) to evaluate the association of circUBAP2 with age, sex, tumor size, stage, differentiation and metastasis. The stability of the results from meta-analysis was estimated via sensitivity analysis. Begg’s funnel plots and Egger’s test were used to appraise the potential publication bias. Subgroup analysis for overall survival (OS) based on follow-up duration, tumor type, case number and survival endpoints were also performed.
resultsHigh expression of circUBAP2 was significantly related to larger tumor size (OR = 3.07, 95% CI: 1.53–6.17, P < 0.05), advanced stage (OR = 2.43, 95% CI: 1.70–3.48, P < 0.05), poor differentiation (OR = 4.47, 95% CI: 2.67–7.48, P < 0.05) and metastasis (OR = 5.77, 95% CI: 3.21–10.40, P < 0.05), but not associated with age or sex. Additionally, circUBAP2 was related to cancer survival (HR = 2.43, 95% CI: 1.96–3.03, P < 0.05), regardless of follow-up duration, tumor type, case number, and survival endpoints. Begg’s funnel plot and Egger’s test showed no publication bias.
conclusionsHigh expression of circUBAP2 may predict larger tumor size, poor differentiation, distant metastasis and poor outcome of cancer, highlighting the carcinogenetic role of circUBAP2 in human cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.